CDK6 and esophageal adenocarcinoma: Knockdown of CDK6 or CDK4 with small interfering RNA or pharmacologic inhibition with palbociclib led to proliferation suppression and inhibition of anchorage-independent survival in esophageal adenocarcinoma cells [21].